前瞻性语句
该沟通包含陈述，在这些陈述中，它们不是历史或当前事实的陈述，而是证券法所构成的“前瞻性陈述”。向公众发布的其他信息时，口头或书面前瞻性陈述不时也可能包括在内。这些前瞻性陈述旨在根据当前认为有效的假设提供Orthofix和Seaspine各自的管理层对我们未来运营和财务绩效的当前期望或计划。可以通过使用诸如“相信”，“期望”，“计划”，“战略”，“前景”，“估算”，“项目”，“目标”，“目标”，“目标”，“目标”等词来确定前瞻性陈述。“预期”，“威尔”，“应该”，“见”，“指导”，“前景”，“自信”，“正轨”和其他类似含义的词。前瞻性陈述可能包括与未来销售，收入，现金流，经营业绩，现金，税率，研发支出，其他财务绩效措施，潜在的未来计划，策略或交易的措施有关的陈述，信用评级和净债务，拟议合并的其他预期收益，包括拟议中的合并产生的估计协同作用和成本节省，预期的合并完成时间，拟议合并的预期时间，与此类交易相关的估计成本以及其他不是历史事实的陈述。所有前瞻性陈述都涉及风险，不确定性和其他可能导致实际结果与前瞻性陈述中表示或暗示的因素。对于这些陈述，我们声称保护安全港对1995年《美国私人证券诉讼改革法案》中包含的前瞻性陈述。这种风险，不确定性和其他因素包括但不限于：（1）经济状况对经济状况的影响Orthofix和Seaspine在美国和全球运营的行业和市场以及其中的任何变化，包括金融市场状况，商品价格的波动，利率和外币汇率以及外币汇率的波动以及医疗保健领域的市场需求水平 which our products are purchased and utilized; (2) challenges in the development, regulatory approval, commercialization, reimbursement, market acceptance, performance and realization of the anticipated benefits of new products of the combined company; (3) the scope, nature, impact or timing of the proposed merger, including among other things the integration of the businesses and realization of synergies and opportunities for growth and innovation and incurrence of related costs and expenses; (4) future levels of indebtedness, capital spending and research and development spending; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) delays and disruption in delivery of materials and services from suppliers; (7) cost reduction efforts and restructuring costs and savings; (8) new business and investment opportunities; (9) the ability to realize the intended benefits of organizational changes; (10) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (11) the effect of changes in political conditions in the U.S. and other countries in which Orthofix, SeaSpine and the businesses of each operate, including the effect of changes in U.S. healthcare policies, on general market conditions in the near term and beyond; (12) the effect of changes in tax, regulatory and other laws and regulations in the U.S. and other countries in which Orthofix, SeaSpine and the businesses of each operate; (13) negative effects of the announcement or pendency of the proposed merger on the market price of Orthofix and/or SeaSpine’s respective common stock and/or on their respective financial performance; (14) the ability of the parties to receive the required regulatory approvals for the proposed merger (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction) and approvals of Orthofix’s and SeaSpine’s shareholders and to satisfy the other conditions to the closing of the merger on a timely basis or at all; (15) the occurrence of events that may give rise to a right of one or both of the parties to terminate the merger agreement; (16) risks relating to the value of the Orthofix shares to be issued in the proposed merger, significant transaction costs and/or unknown liabilities; (17) the possibility that the anticipated benefits from the proposed merger cannot be realized in full or at all or may take longer to realize than expected, including risks associated with third party contracts containing consent and/or other provisions that may be triggered by the proposed transaction; (18) risks associated with transaction-related litigation; (19) the possibility that costs or difficulties related to the integration of Orthofix’s and SeaSpine’s operations will be greater than expected; (20) the ability of the combined company to retain and hire key personnel; (21) the intended qualification of the merger as a tax-free reorganization to Orthofix and SeaSpine shareholders for U.S. federal income tax purposes; and (22) the impact of the proposed merger on the respective businesses of Orthofix and SeaSpine. There can be no assurance that the proposed merger will in fact be consummated in the manner described or at all. For additional information on identifying factors that may cause actual results to vary materially from those stated in forward-looking statements, see the reports of Orthofix and SeaSpine on Forms 10-K, 10-Q and 8-K filed with or furnished to the Securities and Exchange Commission (the “SEC”) from time to time. Any forward-looking statement speaks only as of the date on which it is made, and Orthofix and SeaSpine assume no obligation to update or revise such statement, whether as a result of new information, future events or otherwise, except as required by applicable law.
有关拟议交易以及在哪里找到的其他信息
与拟议的交易有关，Orthofix打算向SEC提交有关表格S-4的注册说明，其中包括一份文档，该文件用作Orthofix的招股说明书以及Orthofix和Orthofix和Seaspine的联合代理声明（“联合代理声明”/招股说明书”）。各方还计划就拟议的交易向SEC提交其他相关文件。敦促投资者和安全持有人阅读联合代理声明/招股说明书以及在SEC可用时提交的其他相关文件，因为它们将包含有关拟议交易的重要信息。确定的联合代理声明/招股说明书将发送给Orthofix的股东和Seaspine的股东。投资者和安全持有人可以免费获得联合代理声明/招股说明书的免费副本（如果和何时可用）以及Orthofix和Seaspine在SEC网站www.sec.gov上向SEC提交的其他相关文件。Orthofix向SEC提交的文件的副本将在Orthofix网站http://ir.www.zctlife.com/上免费获得，或通过（214）937-3190与Orthofix的投资者关系联系。Seaspine向SEC提交的文件的副本将在Seaspine网站http://investor.seaspine.com/上免费获得，或通过（415）937-5402与Seaspine的投资者关系联系。
Orthofix和Seaspine及其各自的董事，执行官和其他管理人员和员工的其他成员可能被视为参与拟议交易的参与者。有关Orthofix的董事和执行官的信息可在2022年年度会议的Orthofix代理声明中获得，该声明于2022年4月27日向SEC提交。有关Seaspine代理声明的董事和海军执行官的信息2022年年度会议于2022年4月22日向美国证券交易委员会提起。有关代理招标参与者的其他信息以及对其直接和间接利益的描述，即安全控股或其他方式，将包含在联合代理声明/招股说明书和其他相关材料可在SEC提出有关拟议交易的可用时。投资者在做出任何投票或投资决策之前可用时应仔细阅读联合代理声明/招股说明书。如上所述，投资者可以从Orthofix和Seaspine获取这些文件的免费副本。
此通信和本文所包含的信息不得构成出售或征集购买任何证券的要约，也不应在任何司法管辖区出售任何证券，在注册之前，此类要约，招标或出售将是非法的或根据任何此类司法管辖区的证券法规定的资格。除了符合1933年《证券法》第10条的要求之外，不得提供证券。
参考
1.从2022年到2025年的复合年增长率
2.不包括基于股票的薪酬
3. IDATA骨骼生长刺激器市场 /电刺激设备市场，美国2018年
4.SmartTrak® - 2021年美国蜂窝同种异体移植市场 - 收入/股票
5.SmartTrak® - 美国仪器融合市场（2020-2026E CAGR）
6.截至2022年9月30日的最新十二个月